Similar Items: Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
- Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study
- Efficacy, Safety, and Tolerability of Atogepant in Migraine Patients from the UAE
- A focus on quality of life and a swift return to normal activities for migraine sufferers
- Perampanel as add‐on in high‐grade glioma–related epilepsy: Seizure control and QoL in a prospective, multicenter, real‐world 6‐month follow‐up study
- Sex differences in neural stress responses over psychosocial stress exposure
- Spectral Composition of Ambient White Light Modulates Photophobia and Headache Intensity During Migraine Attacks